Dimiracetam
| |
| Names | |
|---|---|
| IUPAC name
(RS)-3,6,7,7a-Tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C6H8N2O2 | |
| Molar mass | 140.142 g·mol−1 |
| Pharmacology | |
| Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Dimiracetam is a nootropic drug of the racetam family,[1] derivatives of which may have application in the treatment of neuropathic pain.[2]
Legality
[edit]Australia
[edit]Dimiracetam is a schedule 4 substance in Australia under the Poisons Standard (February 2020).[3] A schedule 4 substance is classified as "Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription."[3]
References
[edit]- ^ Pinza M, Farina C, Cerri A, Pfeiffer U, Riccaboni MT, Banfi S, et al. (December 1993). "Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers". Journal of Medicinal Chemistry. 36 (26): 4214–20. doi:10.1021/jm00078a011. PMID 8277504.
- ^ Farina C, Gagliardi S, Ghelardini C, Martinelli M, Norcini M, Parini C, et al. (March 2008). "Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain". Bioorganic & Medicinal Chemistry. 16 (6): 3224–32. doi:10.1016/j.bmc.2007.12.015. PMID 18171618.
- ^ a b Poisons Standard February 2020. comlaw.gov.au
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |